Galectin Therapeutics (GALT) Return on Capital Employed (2011 - 2026)
Galectin Therapeutics' quarterly Return on Capital Employed came in at 157.32% in Q1 2026, down 19912.0% year-on-year from N/an in Q1 2025, and up 36.02% quarter-over-quarter from 245.88% in Q4 2025.
Galectin Therapeutics has reported Return on Capital Employed for 16 years, with the latest figure at 157.32% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 19912.0% year-over-year to 157.32%; the trailing twelve-month figure through Mar 2026 stood at 157.32% (down 19912.0% YoY), and the FY2025 full-year result was 191.59%, down 52939.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 157.32%, up from 245.88% in the prior quarter.
- The five-year high for Return on Capital Employed was 348.51% in Q4 2024, with the low at 1899.27% in Q2 2025.
- Average Return on Capital Employed over 5 years is 382.77%, with a median of 285.45% recorded in 2022.
- Peak annual rise in Return on Capital Employed reached 131876 bps in 2025, while the deepest fall reached 157295 bps in 2025.
- Tracing GALT's Return on Capital Employed over 5 years: stood at 582.19% in 2022, then surged by 31 bps to 400.53% in 2023, then surged by 187 bps to 348.51% in 2024, then slumped by 171 bps to 245.88% in 2025, then surged by 36 bps to 157.32% in 2026.
- The last three Return on Capital Employed figures came in at 157.32% (Q1 2026), 245.88% (Q4 2025), and 23.85% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -157.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.32% |
| Dec 31, 2025 | -245.88% |
| Sep 30, 2025 | 23.85% |
| Jun 30, 2025 | -1,899.27% |
| Mar 31, 2025 | 41.80% |
| Dec 31, 2024 | 348.51% |
| Sep 30, 2024 | -1,294.91% |
| Jun 30, 2024 | -326.32% |
| Mar 31, 2024 | -259.35% |
| Dec 31, 2023 | -400.53% |
| Sep 30, 2023 | -369.28% |
| Jun 30, 2023 | -373.53% |
| Mar 31, 2023 | -420.29% |
| Dec 31, 2022 | -582.19% |
| Sep 30, 2022 | -285.45% |
| Jun 30, 2022 | -187.00% |
| Mar 31, 2022 | -119.91% |
| Dec 31, 2021 | -97.67% |
| Sep 30, 2021 | -111.54% |
| Jun 30, 2021 | -127.93% |
| Mar 31, 2021 | -121.27% |
| Dec 31, 2020 | -88.72% |
| Sep 30, 2020 | -59.10% |
| Jun 30, 2020 | -46.14% |
| Mar 31, 2020 | -32.59% |
| Dec 31, 2019 | -28.72% |
| Sep 30, 2019 | -22.17% |
| Jun 30, 2019 | -37.98% |
| Mar 31, 2019 | -156.98% |
| Dec 31, 2018 | -176.58% |
| Sep 30, 2018 | -140.17% |
| Jun 30, 2018 | -221.90% |
| Mar 31, 2018 | -684.00% |
| Dec 31, 2017 | -620.59% |
| Sep 30, 2017 | -482.45% |
| Jun 30, 2017 | -228.14% |
| Mar 31, 2017 | -186.19% |
| Dec 31, 2016 | -176.44% |
| Sep 30, 2016 | -164.69% |
| Jun 30, 2016 | -135.81% |
| Mar 31, 2016 | -103.30% |
| Dec 31, 2015 | -88.85% |
| Mar 31, 2015 | -54.06% |
| Dec 31, 2014 | -53.59% |
| Sep 30, 2014 | -45.92% |
| Jun 30, 2014 | -43.36% |
| Mar 31, 2014 | -62.83% |
| Dec 31, 2013 | -156.00% |
| Sep 30, 2013 | -198.07% |
| Jun 30, 2013 | -233.87% |
| Mar 31, 2013 | -161.41% |
| Dec 31, 2012 | -113.27% |
| Sep 30, 2012 | -100.68% |
| Jun 30, 2012 | -79.26% |
| Mar 31, 2012 | -115.76% |
| Dec 31, 2011 | -202.41% |
| Sep 30, 2011 | -113.80% |